Mineralys Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Mineralys Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has a cash flow conversion efficiency ratio of -0.059x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.56 Million) by net assets ($550.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mineralys Therapeutics, Inc. Common Stock (2020–2025)
Cash flow conversion efficiency of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025. This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Mineralys Therapeutics, Inc. Common Stoc for real-time trading data and today's change.
Mineralys Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Mineralys Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mineralys Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Mineralys Therapeutics, Inc. Common Stoc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Digiwin Software Co Ltd
SHE:300378
|
-0.091x |
|
ROBEX Resources Inc
AU:RXR
|
0.047x |
|
BH Macro Limited
LSE:BHMG
|
0.014x |
|
Rumble Inc.
NASDAQ:RUM
|
-0.035x |
|
Ellington Financial Inc.
NYSE:EFC
|
0.416x |
|
Companhiade Eletricidade do Estado da Bahia - COELBA
SA:CEEB3
|
-0.001x |
|
AnaptysBio Inc
NASDAQ:ANAB
|
-2.033x |
|
Daqo New Energy Corp ADR
NYSE:DQ
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Mineralys Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025. Review Mineralys Therapeutics, Inc. Common Stoc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $646.69 Million | $-142.42 Million | -0.220x | +74.68% |
| 2024-12-31 | $191.26 Million | $-166.31 Million | -0.870x | -158.34% |
| 2023-12-31 | $241.15 Million | $-81.17 Million | -0.337x | -160.21% |
| 2022-12-31 | $-52.27 Million | $-29.22 Million | 0.559x | -11.97% |
| 2021-12-31 | $-22.93 Million | $-14.56 Million | 0.635x | -7.25% |
| 2020-12-31 | $-3.60 Million | $-2.46 Million | 0.685x | -- |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, an… Read more